Cargando…

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination

Vaccination is crucial in combatting the severe acute respiratory syndrome coronavirus 2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against platelet factor 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Handtke, Stefan, Wolff, Martina, Zaninetti, Carlo, Wesche, Jan, Schönborn, Linda, Aurich, Konstanze, Ulm, Lena, Hübner, Nils-Olaf, Becker, Karsten, Thiele, Thomas, Greinacher, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Thrombosis and Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105122/ https://www.ncbi.nlm.nih.gov/pubmed/33945605 http://dx.doi.org/10.1182/blood.2021012064

Ejemplares similares

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
por: Greinacher, Andreas, et al.
Publicado: (2021)

COVID-19 and VITT: same or different?
por: Arepally, Gowthami M.
Publicado: (2021)

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
por: Schönborn, Linda, et al.
Publicado: (2022)

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
por: Greinacher, Andreas, et al.
Publicado: (2021)

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Thiele, Thomas, et al.
Publicado: (2021)

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022)

Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity
por: Zheng, Tony J., et al.
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
por: Karnes, Jason H., et al.
Publicado: (2022)

Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany.
por: Thiele, Thomas, et al.
Publicado: (2021)

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination
por: Lee, Agnes Y. Y., et al.
Publicado: (2022)

Longitudinal Aspects of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

Decline in Pathogenic Antibodies over Time in VITT
por: Schönborn, Linda, et al.
Publicado: (2021)

The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies
por: Longstaff, Colin, et al.
Publicado: (2011)

Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain
por: Andersson, Helena M., et al.
Publicado: (2010)

Harmful or Physiologic: Diagnosing Fibrinolysis Shutdown in a Trauma Cohort With Rotational Thromboelastometry
por: Gomez-Builes, J. Carolina, et al.
Publicado: (2018)

Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury
por: Bain, William, et al.
Publicado: (2019)

Targeting complement activation in COVID-19
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2020)

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
por: Yu, Jia, et al.
Publicado: (2020)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020)

A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies
por: Siegal, Deborah M., et al.
Publicado: (2020)

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up
por: Salisbury, Richard, et al.
Publicado: (2020)

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
por: Giannis, Dimitrios, et al.
Publicado: (2021)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene
por: Sadler, Brooke, et al.
Publicado: (2021)

An alternate covalent form of platelet αIIbβ3 integrin that resides in focal adhesions and has altered function
por: Pijning, Aster E., et al.
Publicado: (2021)

Novel mechanism regulating tissue factor activity
por: Nieuwland, Rienk
Publicado: (2021)

The incidence of cancer-associated thrombosis is increasing over time
por: Mahajan, Anjlee, et al.
Publicado: (2022)

The binding of autotaxin to integrins mediates hyperhomocysteinemia-potentiated platelet activation and thrombosis in mice and humans
por: Han, Lulu, et al.
Publicado: (2021)

Role of ribosomal RNA released from red cells in blood coagulation in zebrafish and humans
por: Alharbi, Abdulmajeed, et al.
Publicado: (2021)

Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation
por: Shim, Young Jun, et al.
Publicado: (2021)

PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke
por: Dhanesha, Nirav, et al.
Publicado: (2022)

Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19
por: Henderson, Michael W., et al.
Publicado: (2022)

Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
por: Wygrecka, Malgorzata, et al.
Publicado: (2022)

Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defects
por: Rawley, Orla, et al.
Publicado: (2022)

A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD
por: Shi, Qizhen, et al.
Publicado: (2022)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c5vr9a1c56i7f1uqu2jog0q1ff